chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient started to have symptoms 3 days after vaccine described as "flu like" fever, chills, nausea, vomiting and vertigo. Symptoms resolved about 3 days later expect the vertigo has persisted. He is still having vertigo now 2 + weeks after having vaccine.
Diplopia an sore eyes, with eventual headache. But right know after this present Strabismus in the right eye.
After getting vaccine patient was waiting in the waiting room. After 5 to 10 minutes patient fainted. Pharmacist called 911. Paramedical people came and took patient to emergency room. We tried to call patient , in the phone number patient gave , but that phone doesn't exist.
Member received 0.25 ml Moderna vaccine IM: according to CDC guidelines should have received 0.5 ml Moderna vaccine.
Body aches; Mild fever 99; This is a spontaneous report from a contactable consumer. A 25-years-old male patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 12Apr2021 11:00 (Batch/Lot Number: EW0162) as SINGLE DOSE for covid-19 immunization, at the age at vaccination of 25 years old.  Medical history included exposure to sars-cov-2 from an unknown date and unknown if ongoing (the reporter's nephew called saying he got tested and had COVID), also reported Exposure to COVID before the first dose of vaccine. The patient's concomitant medications were not reported.  The patient experienced body aches (non-serious) on 14Apr2021 with outcome of recovered on 15Apr2021, mild fever 99 (non-serious) on 14Apr2021 with outcome of recovered on 15Apr2021.  The patient underwent lab tests which included body temperature: 99 on unknown date. Reporter stated he got the Pfizer COVID 19 vaccine shot second dose on Tuesday. However the reporters son had the first shot on Monday and his son had went out with friends over the weekend and the reporter's nephew was there. Reporter stated his son got the shot on Monday. Reporter stated Monday night the reporter's nephew called saying he got tested and had COVID. Reporter stated his son had body aches and a mild fever of 99 and is fine today and is wondering is there a problem? Reporter stated his son went to bed and when he got up he was fine this morning. Body aches: Reporter stated his son had this yesterday afternoon and woke up this morning and was fine. Treatment: Reporter stated no because they were not sure since the thing said not to take anything before. Reporter stated he remembered they said one can take something after but reporter told his son do not take anything since it is better for the vaccine. Reporter stated his son did not get these symptoms until after the shot. Reporter stated the paperwork from Pfizer listed all the symptoms possibly could have and his son has a couple and figured the symptoms were from the vaccine.    No follow-up attempts are needed. No further information is expected.
severe headache,muscle ache,fever,nausea,vomitting,local pain of injection,malaise
IMM.  Patient given 3rd Rotateq PO; 3rd Hepatitis B, IM; Prevnar13; and 3rd Pentacel IM around 10:30.   She then went to facility where it was reported to RN about 11:40 that patient was developing a rash on back of neck and hands.   Called to clinic then to note a slightly fussy and tired infant with a pink, slightly raised circular rash in the folds of the neck and on the upper back, left forearm and right cheeks.   During the conversation additional spots were noted on the forehead.   Child has never had this rash before.  Child sleepy.   Patient breathing easy, lung sounds clear, bilaterally.   Dr's office called and informed phone triage nurse of child's condition.  Informed office of HD's rash post shots protocol and to let Dr. on call be aware that epinephrine would be given according to our rash protocol and child possibly transported to ER.  0.1cc of epinephrine given IM in the RT. vast lat. IM per HD standing order at 11:55.   At 11:58 EMT arrived. Report given and child transported in Mom's arms to ambulance for hospital.  Child's cheeks slightly pale, but still sleepy and breathing easy.
5/3/21: 2nd Moderna COVID vaccine in the upper left arm; 5/12/21: I notice a lump underneath the skin of my right forearm; (I wait awhile to see if it will disappear on its own to avoid seeming paranoid) 6/2/21: In-person doctor appointment - my doctor did sight/touch examination on lump and diagnosed it as a (benign) lipoma requiring no treatment.  If I push or rub on the lipoma it's sore afterwards for a couple of days; otherwise, I forget it's even there since I cannot see it - I can only feel it.
A few weeks after my 2nd injection I noticed a lymph node in my arm pit/side of chest that was inflamed. It caused some discomfort and randomly goes away and comes back. I heard from friends they had this reaction as well.
Patient noticed significant swelling and pain on her left arm and side after vaccinations.  By the time she presented to the pharmacy after vaccination, it had been 5 days and the swelling was going down.
Upper left arm from the elbow to upper arm is bright red, swollen, and warm to touch. Shot given on 3-1-16 and over a week progressed to increased inflammation. On 3-8-16 went to dr. Dr prescribed cephalexin 500 mg TID x 7 days and OTC.
Upper arm soreness; intense headache; fever; general feeling of lethargy and a feeling of being spaced out; This is a spontaneous report from a contactable consumer (reported for himself). A 52-years-old male patient received second dose bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: 3248/Batch number was not reported), dose 2 via an unspecified route of administration, administered in arm left on 24Mar2021 at 15:00 (at the age of 52-years-old) as dose 2, single for covid-19 immunisation at Workplace clinic. Medical history included covid-19 from an unknown date and unknown if ongoing (Prior to vaccination, was the patient diagnosed with COVID-19: Yes). The patient concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient has been diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient has no reported allergies. The patient previously received first dose bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot/Batch number was not reported), dose 1 via an unspecified route of administration on 03Mar2021 at 15:00 (at the age of 52-years-old) as dose 1, single for covid-19 immunisation at Workplace clinic. On 25Mar2021 at 09:00, the patient experienced upper arm soreness, intense headache, fever and general feeling of lethargy and a feeling of being spaced out. No treatment was given for the events. The outcome of the events was resolved on an unspecified date in 2021.  Follow-up attempts completed. No further information expected.
hives/she "thought it was bug bite" but says 1-2 new hives appear daily; itching; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives/she "thought it was bug bite" but says 1-2 new hives appear daily) and PRURITUS (itching) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011F21A, 028L20A and 016M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In October 2021, the patient experienced URTICARIA (hives/she "thought it was bug bite" but says 1-2 new hives appear daily) and PRURITUS (itching). At the time of the report, URTICARIA (hives/she "thought it was bug bite" but says 1-2 new hives appear daily) had not resolved and PRURITUS (itching) outcome was unknown.            Concomitant medication was not provided.  Treatment information was not provided.   This case was linked to MOD-2021-380792 (Patient Link).
If it's been six weeks since my first dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (If it's been six weeks since my first dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (If it's been six weeks since my first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (If it's been six weeks since my first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment information was reported.   Reporter did not allow further contact
Pt recvd 3rd vax then devel diarrhea & abdominal cramping; MAY91 c/o h/a & double vision; MAY91 began to bruise easily; dx thrombocytopenia; also anemia & joint aches & pains; JAN92 dx ITP; also rash, lupus, herpes; cholecystectomy;
shivering; breathing heavily; felt like he was still in the dream he had at that time; This is a spontaneous report from a non-contactable consumer (patient). A 24-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0169) via an unspecified route of administration on an unknown date (at the age of 24-years-old) as dose number unknown, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unknown date, the patient woke up 3 hours after he fell asleep, shivering and breathing heavily. The patient felt like he was still in the dream he had at that time. The clinical outcome of the events was unknown at the time of this report.  No follow-up attempts are possible. No further information is expected.  Amendment: This follow-up report is being submitted to amend previously reported information: New event (felt like he was still in the dream he had at that time) added.
muscle or body ache; Fever; Chills; Fatigue; Headache; Joint pain; Nausea; Vomited once; arm stiffness; felt pain bearable; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL STIFFNESS (arm stiffness), VACCINATION SITE PAIN (felt pain bearable), MYALGIA (muscle or body ache), PYREXIA (Fever) and CHILLS (Chills) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Dec-2020, the patient experienced VACCINATION SITE PAIN (felt pain bearable). On 30-Dec-2020, the patient experienced MUSCULOSKELETAL STIFFNESS (arm stiffness), MYALGIA (muscle or body ache), PYREXIA (Fever), CHILLS (Chills), FATIGUE (Fatigue), HEADACHE (Headache), ARTHRALGIA (Joint pain), NAUSEA (Nausea) and VOMITING (Vomited once). At the time of the report, MUSCULOSKELETAL STIFFNESS (arm stiffness), VACCINATION SITE PAIN (felt pain bearable), MYALGIA (muscle or body ache), PYREXIA (Fever), CHILLS (Chills), FATIGUE (Fatigue), HEADACHE (Headache), ARTHRALGIA (Joint pain), NAUSEA (Nausea) and VOMITING (Vomited once) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant and treatment information not provided. Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 12-Apr-2021: Follow-up received on 12 Apr 2021 included no new information; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Child received immunizations on 10/28/08 around 11:00 AM, he developed fever about 700PM that evening, per mother of child. He cried at intervals thru the night, the next AM he was noted having a high pitch cry and loss of appetite. He was taken to Hospital ER that evening with temp of 103 degrees. Childs crying was secondary to pain from immunizations. Pt was tx with Tylenol. Mom states child continued a high pitch cry at intervals until 11/3/08. Fever abated on 11/2/08, Mom told incident to Health Dept on 11/5/08.
Swollen painful lymph nodes under right arm (injection side) x1-2 days; This is a spontaneous report from a contactable consumer. This contactable 41-year-old female consumer (patient) reported for herself.  A 41-years-old female patient (non-pregnant) received (BNT162B2, formulation: Solution for injection, Lot Number: EL 3249), via an unspecified route of administration, administered in Arm Right on 08Jan2021 12:00 pm (at the age of 41-years-old) as DOSE 2, SINGLE, dose 1 via an unspecified route of administration, administered in Arm Right on 18Dec2020 01:00 PM (Batch/Lot Number: EL 0140) as DOSE 1, SINGLE for covid-19 immunization. The patient was not pregnant at the time of vaccination. The patient medical history included blood cholesterol increased and iron deficiency anaemia from an unknown date and unknown if ongoing. The patient concomitant medication (within 2 weeks of vaccination) included nifedipine, oxymetazoline hydrochloride, ethinylestradiol, norgestimate and atorvastatin all are taken for an unspecified indication, start and stop date were not reported . Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced swollen painful lymph nodes under right arm (injection side) x1-2 days on 09Jan2021 12:00. The patient did not receive treatment for event. Device date was reported as 16Aug2021.  The clinical outcome of the event was recovered on an unspecified date.  Follow-up attempts are completed. No further information is expected.
Itching on scalp and back, itching around lips, tingling on lips, and feeling of swollen lips.
Vaccine recipient reported that in the afternoon after receiving their vaccine, they experience severe headache and nausea. They also developed chills, body ache, and arm pain at night. On a follow up call on 1/11/2021, they reported that their symptoms resolved on 1/8/2021.
No adverse event; We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 043H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 17-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 17-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (We gave 30 doses of Moderna bivalent vaccine after manufacturer's expiration date of 08Jun2023).    Concomitant product use was not provided by the reporter.  On 10-Jun-2023, the vial was initially thawed.  On 17-Jun-2023, the vial was administered with 2.  Treatment information was not provided.  This case contains information for the 15th patient out of 30 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-732645 (E2B Linked Report). This case was linked to MOD-2023-733204 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 07-Jul-2023: Live follow-up information received included Suspect details and narrative was updated.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-732645:master case (Patient 1)
Next morning after shot, painful, swolen, knot-like feeling at injection site.  Several days pain subsides, knot subsides, redness and swelling lighten.  Nine days ongoing, light red large circle around injection site still there.  Not painful now, but persistent.  Am somewhat concerned about getting second dose if still there or spreads.
This is a spontaneous report from a contactable physician and nurse via a Pfizer sales representative. This physician and nurse reported same events for 6 patients. This is 4th of 6 reports. An approximately 16-year-old patient of an unspecified ethnicity and gender received the first shot of series for TRUMENBA, via an unspecified route of administration on an unspecified date at single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced rash\hives following first dose of meningococcal group b rlp2086 after use of product on an unspecified date. The outcome of the event was recovered after few days. Sender's Comments: Linked Report(s): US-PFIZER INC-2017286355 same reporter/product/event, different patient.
Eye and cheecks began tingling and swelling within about 30 min. Back of throat felt swollen. Felt light-headed. Heart started racing intermittently. Tingling started subsiding around 8pm. Woke up feeling light-headed and unable to keep focussed attention. Nauseous, and weak. Facial swelling was almost gone. Began getting parasthesias in extremities.  Still with palpations. Symptoms lasted approximately 10 days before starting to improve.
Arthritis Pain improved; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Arthritis Pain improved) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012L20A and 030M20A) for COVID-19 vaccination.     The patient's past medical history included Knee replacement on 27-Apr-2021. Concomitant products included ETANERCEPT (ENBREL), METHOTREXATE, HYALURONATE SODIUM (EUFLEXXA), CENTRUM SILVER +50, CHONDROITIN SULFATE SODIUM, GLUCOSAMINE HYDROCHLORIDE (GLUCOSAMINE/CHONDROITIN [CHONDROITIN SULFATE SODIUM;GLUCOSAMINE HYDROCHLORIDE]), CALCIUM, ZINGIBER OFFICINALE ROOT (GINGER ROOT EXTRACT), FOLIC ACID, CINNAMOMUM CASSIA BARK, THIOCTIC ACID (CINNAMON ALPHA LIPOIC ACID), BIFIDOBACTERIUM BIFIDUM, BIFIDOBACTERIUM LONGUM, LACTOBACILLUS GASSERI (PHILLIPS COLON HEALTH), OMEPRAZOLE, ROSUVASTATIN, ACETYLSALICYLIC ACID (ASPIRIN (E.C.)), CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000), VITAMIN D3 and TOCOPHEROL (VITAMIN E [TOCOPHEROL]) for an unknown indication.   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Arthritis Pain improved). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Arthritis Pain improved) outcome was unknown.            Treatment information was not provided.
After administration the patient passed out and began to seize for under 30 seconds. Patient was unconscious for another minute and woke up before paramedics arrived.
Approximately 5 minutes after receiving the vaccine, pt reported feeling light-headed and a sensation that her heart was racing .  Slightly elevated BP returned to baseline by 1436.
Pt complaint: The pain started at the arm then went to the back, to the waist, went to her nerve. She felt like she had shingles. Patient had a hard time to get up. She went to chiro practice, it helped a little only. Now, patient feels better but still pain. Recommended patient to see her primary doctor.
Urticaria - to ER 2 days after DTaP and Hib given - given Prelone and Benadryl. Returned later in day to pediatrician - hives. Zyrtec syrup ordered.
This spontaneous case, initially received from other non-health professional on 26-Oct-2018, concerns a female patient of an unspecified age. It was reported that whenever flu vaccine was drawn up, it leaked out from the rubber stopper. One of the nurses noticed when they popped the secured lock off the vial the rubber stopper was dented in and off a little. The nurses advised when they removed the hard cap and stuck the needle in the middle, there was a corner on the top where the rubber stopper was dented in causing a hole where the medication would leak. About 5 doses were drawn out of 10 doses in the vial. The vials leaked and only 4 vials were leaking so far. On 05-Oct-2018, the patient was administered FLUCELVAX QIVc [dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: 252234 and expiry date: 30-Jun-2019] from the leaking vial. No adverse events were reported after administration of the vaccine. This case: 201804833 is linked to the original case 201804823 due to the same reporter. This case was associated with product quality complaint, hence quality assurance investigation (QAI) had been requested and the corresponding PTC reference number was 1034101. Based on the QA investigation report, it was concluded that FLUCELVAX Batch 252234 was manufactured in compliance with the approved internal procedures and in accordance with the quality requirements. No internal root cause was identified in the manufacturing process. A known trend was identified for the FLUCELVAX batches from the 2018/2019 FLUCELVAX commercial season for vials leaking at the stopper during dosing. A review revealed that the complainant was adding air to the vial prior to extracting doses and was inverting the vial when withdrawing the needle from the stopper. It was known that the addition of air to the vial can over pressurize the vial and cause leaking. In addition, inverting the vial while trying to extract a dosage can increase the potential for the vial to leak. The root cause for this investigation was found to be user-improper handling. The reporter assessed this case as non-serious. Follow-up report received from QA department on 19-Nov-2018: The QA investigation report stated that, the root cause for the leaking FLUCELVAX MDV of Batch 252234 was due to user or improper handling. Added new event (wrong technique in product usage process) in the event tab. The narrative was amended accordingly.
Within the next three weeks I have experienced severe joint pain in the upper body (shoulders and hands/wrists).  I visited Dr, MD on 11/1/2023 at 08:00 to explain my situation.  Lab tests are scheduled for tomorrow to determine what the cause of the joint pain is.  It could be the onset of arthritis, but the only significant event before the joint pain was the administration of the vaccines.